Skip to Content

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

The combination of daratumumab (Darzalex), ixazomib (Ninlaro), and dexamethasone showed promising results when administered to patients with relapsed/refractory multiple myeloma who had previously received lenalidomide (Revlimid) treatment. These phase 2 DARIA trial results were presented at EHA23 and again in this MEDtalk by Professor Evangelos Terpos from the National and Kapodistrian University of Athens in Greece.

Evangelos Terpos

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top